Alzheimer’s Disease | Unmet Need | Early Alzheimer’s Disease | US/EU5 | 2022

Over the past two decades, in response to mounting failures, clinical trials of disease-modifying therapies (DMTs) in Alzheimer’s disease (AD) have moved earlier in the disease spectrum to increase the probability of success; today, most Phase III clinical trials enroll patients with early AD, commonly comprising mild cognitive impairment (MCI) due to AD and mild AD dementia. In June 2021, Biogen / Eisai’s anti-Aβ MAb aducanumab (Aduhelm) received accelerated approval from the FDA for the treatment of early AD, rendering it the first potential DMT approved for this disease. Although the drug’s approval has been met with considerable controversy, it, nevertheless, marks the dawn of a new era in drug development, disease management, and regulatory standards in this indication. Other DMTs (Eisai / Biogen’s lecanemab, Eli Lilly’s donanemab, Roche’s gantenerumab, Novo Nordisk’s semaglutide) may soon follow. As the AD therapy market enters this new era, it is essential to understand how neurologists perceive the performance of current therapies in early AD patients and their expectations for future DMTs on key clinical and nonclinical attributes.

QUESTIONS ANSWERED

• What are the treatment drivers and goals for early AD?
• What drug attributes are key influences, which have limited impact, and which are hidden opportunities?
• How do current therapies perform on key treatment drivers and goals for early AD?
• What are the prevailing areas of unmet need and opportunity in early AD?
• What trade-offs across different clinical attributes and price are acceptable to U.S. and European neurologists for a hypothetical DMT for early AD?

PRODUCT DESCRIPTION

Provides quantitative insight into U.S. and European physicians’ perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 31 European neurologists fielded in February 2022

Key companies: Eisai, Johnson & Johnson, Novartis, AbbVie, Lundbeck, Grünenthal, Biogen, Eli Lilly, Roche, Novo Nordisk.

Key drugs: donepezil, galantamine, rivastigmine patch, memantine, Namzaric, Aduhelm, lecanemab, donanemab, gantenerumab, and semaglutide.